CA2044855A1 - Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp - Google Patents

Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp

Info

Publication number: CA2044855A1
Authority: CA; Canada
Prior art keywords: pharmaceutical; atp; administered; potassium channel; sulfonyl
Prior art date: 1990-07-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002044855A

Other languages

English (en)

Inventor

Kerry P. S. J. Murphy

Susan A. Greenfield

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-20

Filing date

1991-06-18

Publication date

1992-01-21

1991-06-18 Application filed by Individual filed Critical Individual

1992-01-21 Publication of CA2044855A1 publication Critical patent/CA2044855A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 29
210000002569 neuron Anatomy 0.000 title claims abstract description 24
102000016924 KATP Channels Human genes 0.000 title claims abstract description 14
108010053914 KATP Channels Proteins 0.000 title claims abstract description 14
230000007850 degeneration Effects 0.000 title claims abstract description 12
229940125422 potassium channel blocker Drugs 0.000 title abstract description 4
239000003450 potassium channel blocker Substances 0.000 title abstract description 4
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims abstract description 22
229960005371 tolbutamide Drugs 0.000 claims abstract description 22
229940100389 Sulfonylurea Drugs 0.000 claims abstract description 12
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims abstract description 12
230000003961 neuronal insult Effects 0.000 claims abstract description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
239000001301 oxygen Substances 0.000 claims abstract description 7
229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
-1 for example Chemical compound 0.000 claims abstract description 4
210000004556 brain Anatomy 0.000 claims description 21
210000003523 substantia nigra Anatomy 0.000 claims description 13
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 9
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 8
229960004580 glibenclamide Drugs 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 5
238000009593 lumbar puncture Methods 0.000 claims description 5
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 4
235000001258 Cinchona calisaya Nutrition 0.000 claims description 4
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 4
229960001381 glipizide Drugs 0.000 claims description 4
230000000302 ischemic effect Effects 0.000 claims description 4
229960000948 quinine Drugs 0.000 claims description 4
210000001715 carotid artery Anatomy 0.000 claims description 3
229960001761 chlorpropamide Drugs 0.000 claims description 3
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 3
229960002277 tolazamide Drugs 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
238000001802 infusion Methods 0.000 claims 2
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 abstract 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 28
108091006146 Channels Proteins 0.000 description 25
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
230000002102 hyperpolarization Effects 0.000 description 17
210000004027 cell Anatomy 0.000 description 14
239000012528 membrane Substances 0.000 description 11
102000004257 Potassium Channel Human genes 0.000 description 10
229960003638 dopamine Drugs 0.000 description 10
108020001213 potassium channel Proteins 0.000 description 10
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
230000004044 response Effects 0.000 description 9
238000010304 firing Methods 0.000 description 8
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 7
208000028867 ischemia Diseases 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000009471 action Effects 0.000 description 6
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
230000007423 decrease Effects 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
230000009172 bursting Effects 0.000 description 4
210000001787 dendrite Anatomy 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000000284 resting effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000894007 species Species 0.000 description 4
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
241001573498 Compacta Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
229960001456 adenosine triphosphate Drugs 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
229960003878 haloperidol Drugs 0.000 description 3
230000028161 membrane depolarization Effects 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
206010002660 Anoxia Diseases 0.000 description 2
241000976983 Anoxia Species 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
102000018692 Sulfonylurea Receptors Human genes 0.000 description 2
108010091821 Sulfonylurea Receptors Proteins 0.000 description 2
230000036982 action potential Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000002547 anomalous effect Effects 0.000 description 2
230000007953 anoxia Effects 0.000 description 2
238000003287 bathing Methods 0.000 description 2
230000019522 cellular metabolic process Effects 0.000 description 2
208000029039 cyanide poisoning Diseases 0.000 description 2
230000002999 depolarising effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000000763 evoking effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
229910001414 potassium ion Inorganic materials 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000784713 Cupido Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
102000009467 Sulphonylurea receptors Human genes 0.000 description 1
108050000353 Sulphonylurea receptors Proteins 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
235000015107 ale Nutrition 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
210000001992 atrioventricular node Anatomy 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
125000006309 butyl amino group Chemical group 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000003198 cerebellar cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000003517 fume Substances 0.000 description 1
210000001905 globus pallidus Anatomy 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
210000002660 insulin-secreting cell Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000012241 membrane hyperpolarization Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000000337 motor cortex Anatomy 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002044855A 1990-07-20 1991-06-18 Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp Abandoned CA2044855A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55650290A	1990-07-20	1990-07-20
US556,502		1990-07-20

Publications (1)

Publication Number	Publication Date
CA2044855A1 true CA2044855A1 (fr)	1992-01-21

Family

ID=24221606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002044855A Abandoned CA2044855A1 (fr)	1990-07-20	1991-06-18	Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp

Country Status (3)

Country	Link
EP (1)	EP0467709A3 (fr)
JP (1)	JPH04234329A (fr)
CA (1)	CA2044855A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10533988B2 (en)	2002-03-20	2020-01-14	University Of Maryland, Baltimore	Methods for treating central or peripheral nervous system damage

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994028900A1 (fr) *	1993-06-08	1994-12-22	Vide Pharmaceuticals	Procedes et comositions d'abaissement de la pression intra-oculaire
US5399587A (en) *	1993-12-13	1995-03-21	Merck & Co., Inc.	Biologically active compounds
AUPN193095A0 (en) *	1995-03-24	1995-04-27	Polychip Pharmaceuticals Pty Ltd	Potassium ion channel blockers
GB9819384D0 (en)	1998-09-04	1998-10-28	Cerebrus Ltd	Chemical compounds II
US8980952B2 (en) *	2002-03-20	2015-03-17	University Of Maryland, Baltimore	Methods for treating brain swelling with a compound that blocks a non-selective cation channel
CN101043891A (zh)	2004-09-18	2007-09-26	巴尔的摩马里兰大学	靶向NCCa－ATP通道的治疗剂及其使用方法
EP2111224B1 (fr)	2007-01-12	2016-07-13	University of Maryland, Baltimore	Ciblage de canal ncca-atp destiné à protéger les organes après un épisode ischémique
CA3065983C (fr)	2007-06-22	2022-07-26	The United States Of America As Represented By The Department Of Veterans Affairs	Inhibiteurs de canaux nc<sb>ca-atp</sb> pour therapie

1991
- 1991-06-18 CA CA002044855A patent/CA2044855A1/fr not_active Abandoned
- 1991-07-19 EP EP19910306612 patent/EP0467709A3/en not_active Ceased
- 1991-07-19 JP JP3179524A patent/JPH04234329A/ja not_active Withdrawn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10533988B2 (en)	2002-03-20	2020-01-14	University Of Maryland, Baltimore	Methods for treating central or peripheral nervous system damage

Also Published As

Publication number	Publication date
EP0467709A3 (en)	1992-07-15
JPH04234329A (ja)	1992-08-24
EP0467709A2 (fr)	1992-01-22

Publication	Publication Date	Title
US5215985A (en)	1993-06-01	Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
US5677344A (en)	1997-10-14	Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker
DIXON et al.	1997	Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetlycholine release
AU710770B2 (en)	1999-09-30	A process for regulating vagal tone
DE69530860T2 (de)	2004-05-06	Behandlung der entzündung des sehnervs
US20040068005A1 (en)	2004-04-08	Pharmaceutical combinations
Kline et al.	1997	The diabetogenic effects of acute verapamil poisoning
Zimmer et al.	1994	Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system
Ransom et al.	1990	Anoxic injury of CNS white matter: protective effect of ketamine
Gillespie et al.	1987	Enhanced chemotaxis and superoxide anion production by polymorphonuclear leukocytes from nicotine-treated and smoke-exposed rats
CA2044855A1 (fr)	1992-01-21	Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp
US5236932A (en)	1993-08-17	Method for treating Parkinson's disease employing quinine
LUCOT et al.	1987	Buspirone blocks motion sickness and xylazine-induced emesis in the cat
Gratwohl et al.	1986	Cyclosporine toxicity in rabbits
Pentel et al.	1988	Effects of high dose alpha-1-acid glycoprotein on desipramine toxicity in rats.
Alps	1992	Drugs acting on calcium channels: potential treatment for ischaemic stroke.
Eichner et al.	1974	Treatment of streptozotocin diabetes with di-isopropylammonium dichloroacetate (DIPA)
Gross et al.	1994	Neurotoxicity in conscious rats following intraventricular SNAP, a nitric oxide donor
Garrino et al.	1988	Highly potent and stereoselective effects of the benzoic acid derivative AZ‐DF 265 on pancreatic β‐cells
Gaginella et al.	1975	Inhibition of small intestinal mucosal and smooth muscle cell function by ricinoleic acid and other surfactants
Kim et al.	1987	Multivesicular Liposomes Containing Cytarabine for Slow-Release Sc Administration 1, 2
Friedrichs et al.	1993	Antifibrillatory effects of ibutilide in the rabbit isolated heart: mediation via ATP-dependent potassium channels.
Hirose et al.	1994	Effects of N-[(Trans-4-lsopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) on insulin and glucagon secretion in isolated perfused rat pancreas
Pinto et al.	1982	Cardiac sensitivity to the inhibitory effects of chlorpromazine, imipramine and amitriptyline upon formation of flavins
US20060194810A1 (en)	2006-08-31	Methods of treating ischemic related conditions

Legal Events

Date	Code	Title	Description
1999-06-18	FZDE	Discontinued
2023-05-26	FZDE	Discontinued	Effective date: 19990618

CA2044855A1 - Methode de traitement des agressions contre les neurones susceptibles a la degenerescence parkinsonienne au moyen d'un inhibiteur des vannes a potassium sensibles a l'atp - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=24221606

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (8)

Cited By (1)

Also Published As

Similar Documents

Legal Events